RecruitingNCT05046080

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix - a Rare Tumor

Sponsor

M.D. Anderson Cancer Center

Enrollment

70 participants

Start Date

Aug 6, 2021

Study Type

OBSERVATIONAL

Conditions

Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type

Summary

This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.

Eligibility

Sex: FEMALE

Plain Language Summary

Simplified for easier understanding

This study is collecting and analyzing tissue samples from patients diagnosed with a rare type of cervical cancer called clear cell carcinoma, in order to better understand its biology and improve future treatments. It is a research registry, not a treatment trial. **You may be eligible if...** - You have been diagnosed with clear cell carcinoma of the cervix - You are receiving care at MD Anderson Cancer Center **You may NOT be eligible if...** - You were diagnosed and treated at a different institution and are not a patient at MD Anderson Cancer Center Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERElectronic Health Record Review

Medical records reviewed

OTHERLaboratory Biomarker Analysis

Correlative studies

Locations(1)

M D Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05046080